Unmet Needs in Inoperable Locally Recurrent or Metastatic SCAC
The POD1UM-303/InterAACT 2 phase 3 trial evaluated the addition of the anti‑PD‑1 immunotherapy agent, retifanlimab, to the standard chemotherapy regimen of carboplatin and paclitaxel in patients with inoperable locally recurrent or metastatic SCAC.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Clinical Outcomes, Patterns of Failure, and Salvage Therapies of a Large Modern Cohort of Patients With Anal Squamous Cell Carcinoma Treated With Definitive-Intent Intensity‑Modulated Radiation Therapy
- Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
- Advancements in Immunotherapy for Anal Cancer Treatment
- Background and Current Treatment of Squamous Cell Carcinoma of the Anus
- Genotyping and Cytology Co-Testing for Anal Cancer Screening: Exploratory Evaluation of Cumulative HPV Genotype Burden